Advertisement
UK markets open in 1 hour 6 minutes
  • NIKKEI 225

    39,038.83
    +421.73 (+1.09%)
     
  • HANG SENG

    18,870.72
    -324.88 (-1.69%)
     
  • CRUDE OIL

    76.94
    -0.63 (-0.81%)
     
  • GOLD FUTURES

    2,368.80
    -24.10 (-1.01%)
     
  • DOW

    39,671.04
    -201.95 (-0.51%)
     
  • Bitcoin GBP

    54,492.73
    -400.00 (-0.73%)
     
  • CMC Crypto 200

    1,510.90
    -15.52 (-1.02%)
     
  • NASDAQ Composite

    16,801.54
    -31.08 (-0.18%)
     
  • UK FTSE All Share

    4,560.55
    -23.85 (-0.52%)
     

Struggling 23andMe Granted Extension to Revive Stock Price

(Bloomberg) -- Embattled DNA-testing firm 23andMe Holding Co. has been granted an additional 180 days to move its shares above $1 and avoid being delisted, according to a filing with the Securities and Exchange Commission.

Most Read from Bloomberg

The stock has traded below the $1 Nasdaq minimum since late last year, with the clock is ticking to regain compliance. It will now have until Nov. 4 to regain compliance.

ADVERTISEMENT

23andMe agreed to go public in 2021 via a merger with a special purpose acquisition company founded by billionaire Virgin Group founder Richard Branson. It was valued at $3.5 billion at the time. In just a few years, the stock has lost more than 90% of its value as the consumer DNA testing revolution the company sought has been slow to catch on.

The company didn’t immediately respond to a request for comment.

Last month, Chief Executive Officer Anne Wojcicki said she’s considering taking the company private, telling board members she is proposing to acquire the company, according to a filing. In February, she told Bloomberg she was considering several strategies to revive the stock price, among them splitting the company’s drug-development business from its consumer spit kit business.

Most Read from Bloomberg Businessweek

©2024 Bloomberg L.P.